Insider Transactions in Q1 2021 at Black Diamond Therapeutics, Inc. (BDTX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2021
|
Robert Alexander Ingram |
BUY
Grant, award, or other acquisition
|
Direct |
677
+9.87%
|
$16,248
$24.01 P/Share
|
|
Mar 18
2021
|
Rajeev M. Shah |
BUY
Grant, award, or other acquisition
|
Direct |
443
+50.0%
|
$10,632
$24.01 P/Share
|
|
Mar 18
2021
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
547
+50.0%
|
$13,128
$24.01 P/Share
|
|
Mar 12
2021
|
Brent Hatzis Schoch |
SELL
Open market or private sale
|
Direct |
4,078
-32.68%
|
$106,028
$26.36 P/Share
|
|
Mar 12
2021
|
Brent Hatzis Schoch |
BUY
Exercise of conversion of derivative security
|
Direct |
4,078
+24.63%
|
$12,234
$3.2 P/Share
|
|
Mar 03
2021
|
Christopher D. Roberts Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,500
-25.0%
|
$65,000
$26.21 P/Share
|
|
Mar 03
2021
|
Christopher D. Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+30.49%
|
$25,000
$10.86 P/Share
|
|
Feb 12
2021
|
Brent Hatzis Schoch |
SELL
Open market or private sale
|
Direct |
4,078
-16.87%
|
$110,106
$27.43 P/Share
|
|
Feb 12
2021
|
Brent Hatzis Schoch |
BUY
Exercise of conversion of derivative security
|
Direct |
4,078
+24.63%
|
$12,234
$3.2 P/Share
|
|
Feb 03
2021
|
Christopher D. Roberts Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,500
-43.86%
|
$62,500
$25.35 P/Share
|
|
Feb 03
2021
|
Christopher D. Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+30.49%
|
$25,000
$10.86 P/Share
|
|
Jan 12
2021
|
Brent Hatzis Schoch |
SELL
Open market or private sale
|
Direct |
11,578
-11.49%
|
$370,496
$32.49 P/Share
|
|
Jan 12
2021
|
Brent Hatzis Schoch |
BUY
Exercise of conversion of derivative security
|
Direct |
11,578
+25.96%
|
$81,046
$7.03 P/Share
|
|
Jan 08
2021
|
Thomas Leggett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-100.0%
|
$99,000
$33.94 P/Share
|
|
Jan 08
2021
|
Thomas Leggett Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+50.0%
|
$30,000
$10.86 P/Share
|
|
Jan 04
2021
|
David M. Epstein |
SELL
Open market or private sale
|
Direct |
12,000
-0.85%
|
$372,000
$31.4 P/Share
|
|
Jan 04
2021
|
David M. Epstein |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+0.42%
|
$18,000
$6.42 P/Share
|
|
Jan 04
2021
|
Christopher D. Roberts Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,500
-24.4%
|
$77,500
$31.55 P/Share
|
|
Jan 04
2021
|
Christopher D. Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+30.49%
|
$25,000
$10.86 P/Share
|